JP2017524348A5 - - Google Patents

Download PDF

Info

Publication number
JP2017524348A5
JP2017524348A5 JP2016572566A JP2016572566A JP2017524348A5 JP 2017524348 A5 JP2017524348 A5 JP 2017524348A5 JP 2016572566 A JP2016572566 A JP 2016572566A JP 2016572566 A JP2016572566 A JP 2016572566A JP 2017524348 A5 JP2017524348 A5 JP 2017524348A5
Authority
JP
Japan
Prior art keywords
ptpn2
leukocytes
cell
inhibitor
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016572566A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524348A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2015/050318 external-priority patent/WO2015188228A1/en
Publication of JP2017524348A publication Critical patent/JP2017524348A/ja
Publication of JP2017524348A5 publication Critical patent/JP2017524348A5/ja
Pending legal-status Critical Current

Links

JP2016572566A 2014-06-10 2015-06-10 養子細胞移入のためのｐｔｐｎ２阻害を用いた白血球の産生方法 Pending JP2017524348A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2014902203 2014-06-10
AU2014902203A AU2014902203A0 (en) 2014-06-10 Method of producing cells for adoptive cell transfer
AU2015901171 2015-03-31
AU2015901171A AU2015901171A0 (en) 2015-03-31 Method of producing cells for adoptive cell transfer (2)
PCT/AU2015/050318 WO2015188228A1 (en) 2014-06-10 2015-06-10 Method of producing leukocytes using ptpn2 inhibition for adoptive cell transfer

Publications (2)

Publication Number Publication Date
JP2017524348A JP2017524348A (ja) 2017-08-31
JP2017524348A5 true JP2017524348A5 (enExample) 2018-06-07

Family

ID=54832624

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016572566A Pending JP2017524348A (ja) 2014-06-10 2015-06-10 養子細胞移入のためのｐｔｐｎ２阻害を用いた白血球の産生方法

Country Status (5)

Country Link
US (2) US20170224731A1 (enExample)
EP (1) EP3154555A4 (enExample)
JP (1) JP2017524348A (enExample)
AU (1) AU2015274242A1 (enExample)
WO (1) WO2015188228A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4339287A3 (en) 2015-07-31 2024-05-22 Regents Of The University Of Minnesota Modified cells and methods of therapy
EP4338799A3 (en) 2016-10-18 2024-06-05 Regents of the University of Minnesota Tumor infiltrating lymphocytes and methods of therapy
WO2018148378A1 (en) * 2017-02-08 2018-08-16 Dana-Farber Cancer Institute, Inc. Modulating biomarkers to increase tumor immunity and improve the efficiacy of cancer immunotherapy
CN111511375A (zh) 2017-06-30 2020-08-07 因提玛生物科学公司 用于基因治疗的腺相关病毒载体
WO2019036815A1 (en) * 2017-08-24 2019-02-28 The Royal Institution For The Advancement Of Learning/Mcgill University ENHANCEMENT OF CD8 + T LYMPHOCYTES FOR ADOPTIVE CELL THERAPY BY INHIBITING PTPN1 (PTP1B) AND PTPN2 (TC-PTP))
WO2019178422A1 (en) * 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
CN112040986A (zh) 2018-03-15 2020-12-04 Ksq治疗公司 用于改进的免疫疗法的基因调控组合物和方法
EP3765094A4 (en) 2018-03-15 2021-12-22 KSQ Therapeutics, Inc. GENE REGULATORY COMPOSITIONS AND PROCEDURES FOR IMPROVED IMMUNOTHERAPY
WO2019227176A1 (en) * 2018-06-01 2019-12-05 Monash University Methods of activating cells via ptp 1b inhibition
TWI888352B (zh) 2018-06-21 2025-07-01 美商嘉來克生命科學有限責任公司 蛋白質酪胺酸磷酸酯酶抑制劑及其使用方法
US20220081691A1 (en) * 2018-08-07 2022-03-17 Dana-Farber Cancer Institute, Inc Modulating ptpn2 to increase immune responses and perturbing gene expression in hematopoietic stem cell lineages
SG11202108452WA (en) * 2019-02-04 2021-09-29 Ksq Therapeutics Inc Combination gene targets for improved immunotherapy
KR102983496B1 (ko) 2019-03-14 2026-06-29 칼리코 라이프 사이언시스 엘엘씨 단백질 티로신 포스파타제 억제제 및 이의 사용 방법
US12188045B2 (en) 2019-06-07 2025-01-07 KSQ Therapeutics, Inc. Guide RNA combinations and methods of use
WO2021108455A1 (en) * 2019-11-25 2021-06-03 KSQ Therapeutics, Inc. Methods for activation and expansion of tumor infiltrating lymphocytes
AU2020395612A1 (en) * 2019-12-04 2022-06-09 Monash University Methods of activating cytotoxic leukocytes using PTP1B and PTPN2 inhibitors
AU2020401376A1 (en) * 2019-12-12 2022-06-30 Kumquat Biosciences Inc. Compositions and methods for potentiating immune activity
CN113827727B (zh) * 2020-06-24 2025-04-29 上海交通大学医学院附属瑞金医院 Ptpn2抑制剂在kras突变肿瘤中的应用
MX2024003887A (es) 2021-10-14 2024-07-09 Arsenal Biosciences Inc Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica.
TW202442689A (zh) 2023-03-03 2024-11-01 美商亞森諾生物科學公司 靶向ｐｓｍａ及ｃａ９之系統
WO2024243441A1 (en) 2023-05-24 2024-11-28 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2025075947A1 (en) * 2023-10-06 2025-04-10 Purdue Research Foundation Selective tc-ptp degraders for cancer immunotherapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008043181A1 (en) * 2006-10-12 2008-04-17 Mcgill University Augmenting stem cell populations by modulating t-cell protein tyrosine phosphatase (tc-ptp)
US9217012B2 (en) * 2009-04-08 2015-12-22 Indiana University Research And Technology Corporation Inhibitors of protein tyrosine phosphatases
WO2014039513A2 (en) * 2012-09-04 2014-03-13 The Trustees Of The University Of Pennsylvania Inhibition of diacylglycerol kinase to augment adoptive t cell transfer
WO2014055442A2 (en) * 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
WO2014066137A1 (en) * 2012-10-22 2014-05-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for enhancing cancer immunotherapy
CA2912375C (en) * 2013-05-13 2023-03-14 Cellectis Methods for engineering highly active t cell for immunotherapy
CA2912389C (en) * 2013-06-10 2020-01-28 The General Hospital Corporation D/B/A Massachusetts General Hospital Methods and compositions for reducing immunosupression by tumor cells
CA2977839C (en) * 2014-02-28 2022-07-26 The Royal Institution For The Advancement Of Learning / Mcgill University Tc-ptp inhibitors as apc activators for immunotherapy
RU2752933C2 (ru) * 2014-03-11 2021-08-11 Селлектис Способ создания т-клеток, пригодных для аллогенной трансплантации

Similar Documents

Publication Publication Date Title
US11180730B2 (en) Compositions and methods for evaluating and modulating immune responses by detecting and targeting GATA3
JP2023055884A5 (enExample)
JP2018523668A5 (enExample)
IL300282A (en) Preparations and methods for cell programming using targeted nucleic acid nanocarriers
US20190106678A1 (en) Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
MX2022006854A (es) Composiciones y metodos de arn circular.
JP2019509029A5 (enExample)
US20260078383A1 (en) Rna nanostructures and methods of making and using rna nanostructures
US20170020922A1 (en) Gene editing for immunological destruction of neoplasia
RU2017139121A (ru) Композиции для модулирования экспрессии c9orf72
JP2019527055A5 (enExample)
JP2017508744A5 (enExample)
JP2013530689A5 (enExample)
JP2020528744A5 (enExample)
JP2013521789A5 (enExample)
US20170304418A1 (en) Universal donor checkpoint inhibitor silenced/gene edited cord blood killer cells
JP2019512020A5 (enExample)
JP2018530530A5 (enExample)
WO2020214650A1 (en) Methods and compositions for modulating the immune system
JP2017536826A5 (enExample)
JP2013507934A5 (enExample)
JP2015524413A5 (enExample)
Kher et al. Antisense oligonucleotides and RNA interference
JP2019505210A5 (enExample)
CN101972476B (zh) 利用MicroRNA-155的核酸疫苗佐剂及其构建方法